ZYDUSLIFE Community Narratives

AnalystConsensusTarget's

Fair Value

Fair Value ₹1.2k 5.1% undervalued

Global Healthcare Cost Containment Will Erode Premium Margins

AnalystHighTarget's

Fair Value

Fair Value ₹1.46k 22.1% undervalued

Specialty And Rare Disease Expansion Will Reshape This Diversified Healthcare Leader’s Long-Term Potential

AnalystLowTarget's

Fair Value

Fair Value ₹900.79 26.0% overvalued

Specialty Therapies And Biosimilars Expansion Will Likely Pressure Margins And Earnings

About ZYDUSLIFE

Founded: 1952
Employees: 29980
CEO: Sharvil Patel
WebsiteView website: zyduslife.com

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Consumer Products, and Medical Technologies. The company offers active pharmaceutical ingredients, human and finished dosage formulations, generics, branded generics, specialty formulations, biosimilars, vaccines, novel therapeutics, medical devices and technologies, consumer wellness, veterinary, and animal health products. It also provides biological products in the areas of oncology, autoimmune disorders, nephrology, inflammation, rheumatology, hepatology, and infectious diseases; and designs and executes clinical trials across new chemical entities (NCEs), biologics, vaccines, and specialty generics. In addition, the company operates seasonal, skin and healthcare, and food and nutrition products under the Glucon D, Complan, Sugar Free, Nycil, Everyuth, Nutralite, and RiteBite Max Protein brands. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

Recent ZYDUSLIFE News & Updates

Announcement • Sep 01

Zydus Lifesciences Limited Announces Positive Topline Results From Completed EVIDENCES-X Phase II(b) Clinical Trial Of Saroglitazar Mg In MASH

Zydus Lifesciences Limited announced positive topline results from its completed EVIDENCES-X Phase II(b), prospective, multicentre, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of Saroglitazar Magnesium in patients with Metabolic dysfunction Associated Steatohepatitis (MASH) and fibrosis. The liver biopsy-driven EVIDENCES-X study enrolled 189 subjects who were randomized in a 1:1:1 ratio to receive Saroglitazar 2 mg, Saroglitazar 4 mg or placebo over a treatment period of 52 weeks. The study successfully met its primary endpoint of resolution of steatohepatitis with no worsening of fibrosis at week 52 with the treatment difference of 26.5%. In addition to achieving the primary endpoint, the study demonstrated encouraging findings across key secondary and exploratory endpoints, including improvements in liver histology parameters, steatosis, inflammation and ballooning assessments. Further details would be presented in the upcoming Liver Congress. The EVIDENCES-X trial was led by Prof. Naga Chalasani, M.D., Interim Chair, Department of Medicine, Indiana University School of Medicine, and Prof. Arun J. Sanyal, M.D., Division of Gastroenterology, Virginia Commonwealth University, as co-Principal Investigators. Metabolic dysfunction Associated Steatotic Liver Disease (MASLD) and MASH, continue to represent significant unmet medical needs globally. Experts estimate that approximately 25% of adults worldwide are affected by MASLD, while MASH affects an estimated 5% to 20% of the adult population. MASH is characterized by hepatic steatosis, inflammation, and hepatocellular injury and can progress to advanced fibrosis, cirrhosis, liver failure, liver cancer, and death. The positive results build upon previously published findings from earlier Phase II studies of Saroglitazar in MASH and MASLD patients. Data from the EVIDENCES-X trial will be presented at upcoming scientific meetings and submitted for publication in a peer-reviewed medical journal. Saroglitazar Mg was approved by the Drug Controller General of India (DCGI), for the treatment of MASH and MASLD in India in 2020. Saroglitazar Mg is an investigational compound in the United States and has not yet been approved by the U.S. Food & Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of MASH and MASLD. EVIDENCES-X was a global, multicentre, randomized, double-blind, placebo-controlled Phase II(b) clinical trial designed to evaluate the efficacy and safety of Saroglitazar Magnesium in patients with MASH and fibrosis. The study enrolled 189 patients across USA, Turkey and Argentina randomized to Saroglitazar 2 mg, Saroglitazar 4 mg, or placebo. The primary endpoint was resolution of steatohepatitis with no worsening of fibrosis as assessed by liver biopsy after 52 weeks of treatment. Metabolic dysfunction Associated Steatohepatitis (MASH) is a progressive form of Metabolic dysfunction Associated Steatotic Liver Disease (MASLD) characterized by fat accumulation, inflammation, and liver cell injury. MASH can progress to fibrosis, cirrhosis, hepatocellular carcinoma, liver transplantation, and death, creating a substantial clinical and economic burden worldwide.

Recent updates

No updates

Zydus Lifesciences Limited Stock Price

ZYDUSLIFE Share Price Performance

ZYDUSLIFE Community Narratives

Global Healthcare Cost Containment Will Erode Premium Margins

Specialty And Rare Disease Expansion Will Reshape This Diversified Healthcare Leader’s Long-Term Potential

Specialty Therapies And Biosimilars Expansion Will Likely Pressure Margins And Earnings

Global Healthcare Cost Containment Will Erode Premium Margins

Specialty Therapies And Biosimilars Expansion Will Likely Pressure Margins And Earnings

Specialty And Rare Disease Expansion Will Reshape This Diversified Healthcare Leader’s Long-Term Potential

Trending Discussion

Recently Updated Narratives

ZYDUSLIFE: MASH Trial Optimism Will Likely Mask Overvaluation Risk Ahead

ZYDUSLIFE: COPD Launch And USFDA Outcomes Will Shape Balanced Outlook

ZYDUSLIFE: USFDA Approvals Will Support Future Earnings Re‑Rating

Snowflake Analysis

Zydus Lifesciences Limited Key Details

About ZYDUSLIFE

Recent ZYDUSLIFE News & Updates

ZYDUSLIFE: MASH Trial Optimism Will Likely Mask Overvaluation Risk Ahead

Zydus Lifesciences Limited Announces Positive Topline Results From Completed EVIDENCES-X Phase II(b) Clinical Trial Of Saroglitazar Mg In MASH

ZYDUSLIFE: COPD Launch And USFDA Outcomes Will Shape Balanced Outlook

Recent updates

Zydus Lifesciences Limited Competitors

Sun Pharmaceutical Industries

Divi's Laboratories